A comparison study for efficacy and safety of travoprost 0.004% versus timolol in threatment of early-onset ocular hypertension after vitrecomy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800014942

Enrollment

Unknown

Registered

2018-02-23

Start date

2018-03-01

Completion date

Unknown

Last updated

2018-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ocular hypertension

Interventions

Timolol group:0.05% timolol Bid

PG group:0.004% travoprost qd

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients received 23G PPV by the same surgeon without preventive use of IOP Lowing drugs have ocular hypertension ( IOP=25mmHg and <45mmHg) 2-30 days after PPV, with complete open angle.

Exclusion criteria

Exclusion criteria: history of glaucoma and ocular hypertension, history of ocular trama, history of low heart rate, history of respiratory dieseases, allergic to timilol and travoprost

Design outcomes

Primary

Measure	Time frame
Intraocular pressure;	—

Secondary

Measure	Time frame
numbers of drugs;	—

Countries

China

Contacts

Public ContactYuan Fang

Eye & ENT Hospital of Fudan University

fangyuandoc@163.com+86 18917786129

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026